Below is what the clinical-trial data and user/abuse literature say about pregabalin's positive (pleasurable) subjective effects, organized roughly by dose. Two caveats up front: effects vary enormously between individuals, and the "positive" effects are exactly the ones that drive misuse — tolerance to them develops rapidly. ( Euphoria study)

Low therapeutic range (~75–150 mg/day)

• Users mainly report anxiolysis, physical relaxation, and better sleep — a "background calm" rather than anything intoxicating.
• Euphoria is uncommon here but still above placebo: in pooled trial data "euphoric mood" occurred in 1.6% of pregabalin patients vs 0.2% on placebo, with the lowest rates in the ≤150 mg/day group. ( Comprehensive safety evaluation)

Mid therapeutic range (~150–300 mg/day)

• Reports shift toward a mild sense of well-being, warmth, mental quieting, and sociability, sometimes described as a slightly "floaty" state.
• In generalized anxiety disorder trials at higher doses, 5–12% of patients reported euphoria (vs ~1% on placebo); ~10% of healthy volunteers in pharmacology studies did too. ( ScienceInsights summary of FDA data)
• An FDA abuse-potential study in recreational sedative users found a 200 mg single dose produced "high," "liking," and "good drug effect" comparable to diazepam, and was identified as feeling like a sedative. ( ScienceInsights summary of FDA data)

Upper therapeutic / supratherapeutic (~300–600 mg/day)

• Effects users describe as desirable become much more pronounced: alcohol- or benzodiazepine-like intoxication, disinhibition, talkativeness, and "tipsy" lightness — opioid-using interviewees described using it to feel "tipsy" and to potentiate heroin or cocaine. ( Opioid misuser interviews)
• In the abuse-potential study, the 450 mg dose was rated as more "likeable" than either diazepam dose, and subjects described it as a sedative-stimulant combination rather than a pure sedative. ( ScienceInsights summary of FDA data)
• Analysis of online user reports associates the sought-after sedative and mildly "psychedelic" effects with doses above the clinical range. ( University of Hertfordshire / Schifano analysis)

Far above therapeutic range (misuse typically 3–20× prescribed doses, e.g. >900 mg)

• The reported positive effects here are intense euphoria, dissociation, numbness, empathy, and hallucinations, alongside heavy sedation. ( De-addiction centre study,  Poisoning series)
• This is also the range where the experience stops being pleasant for many: ataxia, confusion, falls, and — especially with opioids, benzodiazepines, or alcohol — coma and respiratory depression appear, and seizures can occur even in overdose cases otherwise rated "mild." ( Poisoning series)
• A meta-analysis found euphoria had one of the largest relative risks of any pregabalin effect (RR ~6.2 vs placebo), with adverse events overall following a clear dose-response relationship. ( Zaccara et al. meta-analysis)

The catch

The pleasurable effects are the trap: tolerance to the euphoria develops quickly, driving dose escalation, and dependence and withdrawal (insomnia, anxiety, nausea, sweating) are well documented even at ordinary therapeutic doses. ( Poisoning series,  Abuse potential review) This profile is why pregabalin is a Schedule V controlled substance in the US and a Class C drug in the UK. ( Abuse potential review)

If this is for research, writing, or harm-reduction content, I'm happy to go deeper on any tier or on the withdrawal/dependence literature.